Winter 2018 Cohort
Yong Ba is a professor in the Department of Chemistry and Biochemistry at Cal State LA. He received his Ph.D. in chemistry from Gerhard Mercator University, Duisburg. His research group’s interest is to develop intellectual properties of biomedical materials including free radical labeled anticancer drugs, controlled release hydrogels, beta-cyclodextrin based drug delivery molecular carriers, biocompatible nanoparticles, and spin-labeled and functionally valued antifreeze proteins. His research team is raising funds to start an entrepreneurial endeavor. He is joined by undergraduate student Adiel Perez.
Nasim Bahadorani holds a doctorate in public health from Loma Linda University. Nasim teaches public health courses at Cal State Northridge. She has developed a health promotion business that focuses on lifestyle medicine with evidence-based programs, and is expanding her public health research with use of biotechnology for measurement of health outcome variables.
Neil Bodie founded Paradigm Immunotherapeutics Inc. in 2014, where he is currently president and CEO. Paradigm is developing disruptive technology for highly infectious agents, such as Ebola, and novel treatments for immune mediated diseases. Bodie has been researching the causes and treatments for autoimmune diseases and viral induced immune mediated diseases since 1997. He is also the lead inventor of seven issued U.S. patents and multiple U.S. and World/PCT patent applications. He earned his doctorate in veterinary medicine at the University of California, Davis.
Nzola De Magalhaes
Nzola De Magalhaes has a Ph.D. in biomedical engineering from the University of California, Irvine. Her research foundation is in photomedicine, biomedical imaging, and basic and translational cancer research. She also has certifications in laser/electro-optics and immunohistotechnology. She recently completed a postdoctoral appointment at the University of California, San Diego, in the department of pathology, where she performed research on targeted therapeutics against pancreatic cancers. She plans to start a venture to further pursue the development of therapeutics against pancreatic cancers.
Cathy Yan Jin is the leader of a team that is developing high quality affordable sensors and services that measure small molecule components, those naturally abundant in foods and beverages, at a low cost. Cathy holds a Ph.D. in physical chemistry from the University of California, Los Angeles. She is currently a postdoctoral researcher at UCLA working on cancer immunotherapy. Cathy is joined by partners Richard W. Sportsman of UCLA and John R. Sportsman.
Vazgen Khankaldyyan has acquired preclinical research expertise in cancer research through interactions with multidisciplinary professionals at Children’s Hospital Los Angeles and City of Hope. Vazgen’s current interest includes connecting with regional bioscience professionals and orchestrating and strategizing combinational therapeutics in drugs, biologics and devices. His goal is to discover the best efficacious therapeutics for personalized medicine. Vazgen received a B.S. in biochemistry and molecular biology from the University of California, Santa Barbara.
Eva Min Yi Lee
Eva Min Yi Lee received a B.S. in botany from the University of California, Riverside, and a B.A. in international business and management from Cal Poly Pomona. She is an entrepreneur in the medical cosmetics (cosmeceutical) industry. She has two years of research experience at UC Riverside, in the Department of Plant Science. Her team includes partners Dr. Mina Hsiung and Lori Price.
Lina Li is seeking new opportunities in the field of nutriceutics and pharmaceutics development following her recent departure from Astellas Pharma. She is currently a principal consultant in bioassay development and testing, providing immunochemistry, cell biology and in vitro pharmacology services to biotech/pharma/food companies. She is a seasoned drug discovery and development scientist with versatile experiences in developing both small molecule- and protein/antibody-based drugs. Lina obtained her M.D. from Tongji Medical University in China.
Fan Liu is developing computational models and databases for neoantigen-based cancer immunotherapy. Fan holds a Ph.D. in chemistry from Caltech. He is a staff scientist at Caltech.
Shabnam Mohandessi is the cofounder and director of Assay Development of SELFA Inc., which is developing a label-free, multiplex and ultrasensitive sample-to-answer biosensor for early detection of infectious diseases and cancers from bodily fluids. Shabnam holds a Ph.D. in biochemistry from the University of Illinois at Chicago. She was a National Institutes of Health postdoctoral fellow at UCLA Medical School before joining SELFA. She is joined by team members, CEO Ira Deyhimy and Director of Technology Kaveh Shoorideh.
Helen Poldsam is the co-founder and CEO of Brainion Therapeutics, the next generation platform for the central nervous system therapeutics. Helen holds a master’s degree in education from Harvard University.
Jonathan Saboury is an undergraduate student at Cal State LA who works in an organic chemistry lab under Dr. Carlos Gutiérrez and is collaborating with Dr. Howard Xu to develop novel efflux pump inhibitors to combat multidrug resistant Gram-negative bacteria. He is also co-founding a company with two colleagues for computer-aided drug design services through optimizing currently available software to run on specialized hardware as well as their own software.
Argus Sun is developing vascular connective tissue constructs for pharmaceutical testing. He holds a Ph.D. in bioengineering from the University of California, Los Angeles. In addition, he worked as a postdoctoral fellow at Sanford Consortium for Regenerative Medicine. His team includes Angus Hsu, a UCLA Anderson MBA graduate with whom he worked with on a tech startup.
Jongseung Yoon is an assistant professor in the Department of Chemical Engineering, Materials Science, and Electrical Engineering at the University of Southern California. He received a Ph.D. in materials science and engineering from MIT. His team at USC is developing VCSEL-based flexible optoelectronic sensors for wearable and personalized diagnostics.